Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor ...

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...